| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/11/2003 | WO2002043758A3 Uses of mammalian genes and related reagents |
| 12/11/2003 | WO2002041884A8 Inhibitors of abc drug transporters at the blood-brain barrier |
| 12/11/2003 | US20030229907 Transgenic non-human mammals with progressive neurologic disease |
| 12/11/2003 | US20030229217 Comprises gamma-amino butyric acid (GABA) receptor subunits for treatment of obesity, vision defects, high blood pressure, depression and sexual disorders |
| 12/11/2003 | US20030229202 Comprises fusion protein for intracelluar delivery of compounds of interest into cells; drug delivery |
| 12/11/2003 | US20030229144 Anti-epileptogenic agents |
| 12/11/2003 | US20030229140 Plant extracts; chlorogenic acid |
| 12/11/2003 | US20030229134 Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type 4 |
| 12/11/2003 | US20030229128 Glucagon receptor antagonists/inverse agonists |
| 12/11/2003 | US20030229114 Central nervous system disorders; Alzheimer's disease, Parkinson's disease; Huntington's disease; strokes |
| 12/11/2003 | US20030229112 Synergistic mixture of temozolomide and irinotecan |
| 12/11/2003 | US20030229097 Potentiation of fungicides |
| 12/11/2003 | US20030229093 Lipid diseases; metabolism diosrders; antiproliferative agents |
| 12/11/2003 | US20030229092 Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens |
| 12/11/2003 | US20030229088 Novel methods and compositions for alleviating pain |
| 12/11/2003 | US20030229083 Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 12/11/2003 | US20030229065 Measuring drug resistance, calibration; reducing antibiotic resistance |
| 12/11/2003 | US20030229064 Method of treating cancer using dithiocarbamate derivatives |
| 12/11/2003 | US20030229061 Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity |
| 12/11/2003 | US20030229057 Continuous sulfatase inhibiting progestogen hormone replacement therapy |
| 12/11/2003 | US20030229053 Compounds and methods for the treatment or prevention of flavivirus infections |
| 12/11/2003 | US20030229048 Skin disorders; antiinflammatory agents |
| 12/11/2003 | US20030229047 Liquid formulation of decitabine and use of the same |
| 12/11/2003 | US20030229044 Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
| 12/11/2003 | US20030229034 Drug delivery; nucleic acids; complexing |
| 12/11/2003 | US20030229029 Cardiac glycosides for treating muscle pain and spasm |
| 12/11/2003 | US20030229025 Antidiabetic agents, eating disorders, dietetics |
| 12/11/2003 | US20030229023 Anticancer agents; skin disorders; antiinflamamtory agents; antiarthritic agents |
| 12/11/2003 | US20030229008 Regenerating organs; anticancer agents; autoimmune disease; stabilization cells |
| 12/11/2003 | US20030229004 Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
| 12/11/2003 | US20030229003 Use of transcription factors for treating inflammation and other diseases |
| 12/11/2003 | US20030229002 Use of agents that modulate PDE11A activity |
| 12/11/2003 | US20030229001 Administering oxytocin antagonist |
| 12/11/2003 | US20030228662 Comprises nucleotide sequences coding tetrodoxin resistant transport protein for diagnosing, prevention and treatment of pain, muscular and cardiac disorders |
| 12/11/2003 | US20030228642 Crohn's disease treatment and efficacy prediction methods |
| 12/11/2003 | US20030228606 Her-2 receptor tyrosine kinase molecules and uses thereof |
| 12/11/2003 | US20030228573 Contacting test compound with Gag283 and determining its ability to bind to the apical cleft near the C-terminal domain; use in treatment of Acquired Immunodeficiency Syndrome (AIDS) |
| 12/11/2003 | US20030228568 Inducible phosphofructokinase and the warburg effect |
| 12/11/2003 | US20030228379 Herbs and herbal combinations useful for the treatment of microbial infections |
| 12/11/2003 | US20030228377 Detoxifying mineral compositions based on zeolites with a high cation exchange capacity |
| 12/11/2003 | US20030228371 Anti-infarction molecules |
| 12/11/2003 | US20030228355 Precipitation of lipid; fineness particle size |
| 12/11/2003 | US20030228340 Applying pyridone/2-/, 1-hydroxy- |
| 12/11/2003 | US20030228320 Administering activator of retrovirus cells; then suppressor or destroying cells |
| 12/11/2003 | US20030228289 Universal chimera bank |
| 12/11/2003 | US20030228281 Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| 12/11/2003 | US20030228274 Immobilization of polypeptide with polyamide-polyether |
| 12/11/2003 | US20030228257 Induction apoptosis; antiarthritic agents |
| 12/11/2003 | CA2494451A1 Treatment of cell proliferative disorders with chlorotoxin |
| 12/11/2003 | CA2491420A1 Rb1 gene induced protein (rb1cc1) and gene |
| 12/11/2003 | CA2488568A1 Methods of diagnosing and treating diabetes and insulin resistance |
| 12/11/2003 | CA2488287A1 Use of a synergistic combination of chlorogenic acid and 3-o-p-coumaryl quinic acid as an anti-leukemic therapy |
| 12/11/2003 | CA2488238A1 Method for reducing obstructive hydrocephalus |
| 12/11/2003 | CA2488013A1 Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| 12/11/2003 | CA2488012A1 Cftr modifier genes and expressed polypeptides useful in treating cystic fibrosis |
| 12/11/2003 | CA2487905A1 Use of cgmp - stimulating compounds |
| 12/11/2003 | CA2487895A1 Defensins: use as antiviral agents |
| 12/11/2003 | CA2487885A1 Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors |
| 12/11/2003 | CA2487730A1 Sgk and nedd used as diagnostic and therapeutic targets |
| 12/11/2003 | CA2487678A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone |
| 12/11/2003 | CA2487639A1 Self-administered contraceptive injection of oily solution |
| 12/11/2003 | CA2487636A1 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
| 12/11/2003 | CA2487585A1 Formulations for amylin agonist peptides |
| 12/11/2003 | CA2487425A1 Combination chemotherapy with chlorotoxin |
| 12/11/2003 | CA2486110A1 Pharmaceutical combination |
| 12/11/2003 | CA2485194A1 Dietary method for modulating glucose metabolism and associated conditions and increasing longevity |
| 12/11/2003 | CA2485080A1 Pharmaceutical composition having a delayed active substance release, and method for the preparation thereof |
| 12/11/2003 | CA2482345A1 Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
| 12/11/2003 | CA2477261A1 Methods for enhancing motor performance and/or endurance |
| 12/10/2003 | EP1369121A1 Detoxifying mineral compositions based on zeolites with a high cation exchange capacity |
| 12/10/2003 | EP1369120A1 Treatment of flavivirus infection |
| 12/10/2003 | EP1368660A2 Assay |
| 12/10/2003 | EP1368648A2 Detection of compounds that modulate inflammatory responses |
| 12/10/2003 | EP1368487A1 Methods involving the use of capg as a diagnostic marker and methods for the identification of capg modulators for the treatment and prevention of osteoporosis and related disease states |
| 12/10/2003 | EP1368473A2 Neurotransmission-associated proteins |
| 12/10/2003 | EP1368470A2 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 12/10/2003 | EP1368469A2 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof |
| 12/10/2003 | EP1368454A1 Method for detecting a risk of hypertension and uses thereof |
| 12/10/2003 | EP1368381A1 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 12/10/2003 | EP1368378A2 Constitutively desensitized g protein-coupled receptors |
| 12/10/2003 | EP1368340A1 Piperazine derivatives as melanocortin receptor agonists |
| 12/10/2003 | EP1368318A2 Calcilytic compounds |
| 12/10/2003 | EP1368308A1 Cannabinoid receptor ligands |
| 12/10/2003 | EP1368061A2 Fusion cells and cytokine compositions for treatment of disease |
| 12/10/2003 | EP1368060A1 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| 12/10/2003 | EP1368054A2 Using neural thread proteins to treat tumors and other hyperproliferative disorders |
| 12/10/2003 | EP1368040A2 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
| 12/10/2003 | EP1368038A1 Methods for the administration of amifostine and related compounds |
| 12/10/2003 | EP1368036A1 Regulation of glucocorticoid concentration |
| 12/10/2003 | EP1368028A1 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
| 12/10/2003 | EP1368026A1 Use of active substance combinations from alpha lipoic acid and substances that absorb light in the uv-a and/or uv-b range for use in the treatment and/or prophylaxis of undesired cutaneous pigmentation |
| 12/10/2003 | EP1368025A2 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor |
| 12/10/2003 | EP1368018A2 Use of sugar phosphate, sugar phosphate analogues, amino acids and/or amino acid analogues for modulating the glycolysis-enzyme complex, the malate-aspartate shuttle and/or transaminases |
| 12/10/2003 | EP1368015A1 Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
| 12/10/2003 | EP1368010A2 Antibacterial compositions which contain oxapenem-3-carboxylic acids and antibiotics |
| 12/10/2003 | EP1368009A2 Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 12/10/2003 | EP1368008A1 Transdermal therapeutic system for the administration of partial dopamine-d2 agonists |
| 12/10/2003 | EP1368006A1 Novel modified released formulation |
| 12/10/2003 | EP1368004A2 Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine |
| 12/10/2003 | EP1367998A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |